Dr Jane Seto
Dr Jane Seto
Details
Role
Team Leader / Senior Research Officer
Research area
Genomic Medicine
Group
Muscle Research
Dr Jane Seto is a Team Leader in the Muscle Research Group at Murdoch Children’s Research Institute.
Dr Seto completed her PhD at the University of Sydney, Australia, in 2010 where she characterised the effects of ACTN3 deficiency in skeletal muscle. ACTN3 deficiency occurs in 1 in 5 people worldwide, and while it does not cause disease, it is associated with reduced muscle mass and strength in elite sprinters and in the general population. For her work in her PhD, Dr Seto was awarded an Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship, as well as the Sir Keith Murdoch Fellowship from the American Australian Association. This funding allowed her to complete 4 years of postdoctoral training with Professor Jeffrey Chamberlain at the University of Washington, USA, an expert in gene and cell therapies for inherited muscle diseases. There, she was trained on the design and testing of recombinant adeno-associated viral vector (rAAV) mediated gene delivery in pre-clinical models of Duchenne muscular dystrophy and limb-girdle muscular dystrophies.
Dr Seto joined the Muscle Research Group in 2014 where she continues her research in ACTN3 deficiency. Leveraging her expertise in therapeutic testing in mouse models, Dr Seto’s current research focus is on the effects of ACTN3 deficiency on the regulation of muscle mass and metabolism and the response to therapies that impact these pathways. She was appointed Team Leader in June 2018. Dr Seto is also an honorary Fellow within the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne where she lectures on Genetics and Sports.
Dr Seto completed her PhD at the University of Sydney, Australia, in 2010 where she characterised the effects of ACTN3 deficiency in skeletal muscle. ACTN3 deficiency occurs in 1 in 5 people worldwide, and while it does not cause disease, it is associated with reduced muscle mass and strength in elite sprinters and in the general population. For her work in her PhD, Dr Seto was awarded an Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship, as well as the Sir Keith Murdoch Fellowship from the American Australian Association. This funding allowed her to complete 4 years of postdoctoral training with Professor Jeffrey Chamberlain at the University of Washington, USA, an expert in gene and cell therapies for inherited muscle diseases. There, she was trained on the design and testing of recombinant adeno-associated viral vector (rAAV) mediated gene delivery in pre-clinical models of Duchenne muscular dystrophy and limb-girdle muscular dystrophies.
Dr Seto joined the Muscle Research Group in 2014 where she continues her research in ACTN3 deficiency. Leveraging her expertise in therapeutic testing in mouse models, Dr Seto’s current research focus is on the effects of ACTN3 deficiency on the regulation of muscle mass and metabolism and the response to therapies that impact these pathways. She was appointed Team Leader in June 2018. Dr Seto is also an honorary Fellow within the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne where she lectures on Genetics and Sports.
Dr Jane Seto is a Team Leader in the Muscle Research Group at Murdoch Children’s Research Institute.
Dr Seto completed her PhD at the University of Sydney, Australia, in 2010 where she characterised the effects of ACTN3 deficiency in skeletal...
Dr Seto completed her PhD at the University of Sydney, Australia, in 2010 where she characterised the effects of ACTN3 deficiency in skeletal...
Dr Jane Seto is a Team Leader in the Muscle Research Group at Murdoch Children’s Research Institute.
Dr Seto completed her PhD at the University of Sydney, Australia, in 2010 where she characterised the effects of ACTN3 deficiency in skeletal muscle. ACTN3 deficiency occurs in 1 in 5 people worldwide, and while it does not cause disease, it is associated with reduced muscle mass and strength in elite sprinters and in the general population. For her work in her PhD, Dr Seto was awarded an Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship, as well as the Sir Keith Murdoch Fellowship from the American Australian Association. This funding allowed her to complete 4 years of postdoctoral training with Professor Jeffrey Chamberlain at the University of Washington, USA, an expert in gene and cell therapies for inherited muscle diseases. There, she was trained on the design and testing of recombinant adeno-associated viral vector (rAAV) mediated gene delivery in pre-clinical models of Duchenne muscular dystrophy and limb-girdle muscular dystrophies.
Dr Seto joined the Muscle Research Group in 2014 where she continues her research in ACTN3 deficiency. Leveraging her expertise in therapeutic testing in mouse models, Dr Seto’s current research focus is on the effects of ACTN3 deficiency on the regulation of muscle mass and metabolism and the response to therapies that impact these pathways. She was appointed Team Leader in June 2018. Dr Seto is also an honorary Fellow within the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne where she lectures on Genetics and Sports.
Dr Seto completed her PhD at the University of Sydney, Australia, in 2010 where she characterised the effects of ACTN3 deficiency in skeletal muscle. ACTN3 deficiency occurs in 1 in 5 people worldwide, and while it does not cause disease, it is associated with reduced muscle mass and strength in elite sprinters and in the general population. For her work in her PhD, Dr Seto was awarded an Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship, as well as the Sir Keith Murdoch Fellowship from the American Australian Association. This funding allowed her to complete 4 years of postdoctoral training with Professor Jeffrey Chamberlain at the University of Washington, USA, an expert in gene and cell therapies for inherited muscle diseases. There, she was trained on the design and testing of recombinant adeno-associated viral vector (rAAV) mediated gene delivery in pre-clinical models of Duchenne muscular dystrophy and limb-girdle muscular dystrophies.
Dr Seto joined the Muscle Research Group in 2014 where she continues her research in ACTN3 deficiency. Leveraging her expertise in therapeutic testing in mouse models, Dr Seto’s current research focus is on the effects of ACTN3 deficiency on the regulation of muscle mass and metabolism and the response to therapies that impact these pathways. She was appointed Team Leader in June 2018. Dr Seto is also an honorary Fellow within the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne where she lectures on Genetics and Sports.
Top Publications
- Seto, JT, Roeszler, KN, Meehan, LR, Wood, HD, Tiong, C, Bek, L, Lee, SF, Shah, M, Quinlan, KGR, Gregorevic, P, et al. ACTN3 genotype influences skeletal muscle mass regulation and response to dexamethasone. 2026 view publication
- Kiriaev, L, Oakhill, JS, Tiong, CF, Seto, JT, Crossman, VG, Quinlan, KGR, North, KN, Houweling, PJ, Ling, NXY. Modern Insights into Muscle Glycogen Phosphorylase Activity. 2026 view publication
- Roeszler, KN, See, M, Meehan, LR, Lima, G, Kolliari-Turner, A, Alexander, SE, Landen, S, Wood, HD, Tiong, CF, Chen, W, et al. ACTN3 genotype influences androgen response in skeletal muscle. 2026 view publication
- Houweling, PJ, Tiong, CF, Kiriaev, L, Díaz-Peña, R, Albers, PK, Wood, H, Wyckelsma, V, Stait, T, Venckunas, T, Valenzuela, PL, et al. α-Actinin-3 deficiency protects from the effects of acute cold exposure through altered skeletal muscle Ca2+ and OXPHOS signaling. 2026 view publication
- Kiriaev, L, Tiong, C, Huckstep, H, Mattes, K, Laier, A, Chandrasena, N, Crossman, V, Seto, J, Humphrey, S, Head, S, et al. Trained to repair: repeated muscle injury imprints a ‘healthy regenerative memory’. 2026 view publication
Page 1 of 11
Career information
Share //
